Last update 08 May 2025

IRAK1/IRAK4/FLT3 inhibitors(National Center for Advancing Translational Sciences)

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Compound 31(National Center for Advancing Translational Sciences)
Target
FLT3 x IRAK1 x IRAK4
Action
inhibitors, antagonists
Mechanism
FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), IRAK1 antagonists(Interleukin-1 receptor-associated kinase 1 antagonists), IRAK4 inhibitors(Interleukin-1 receptor-associated kinase 4 inhibitors)
Therapeutic Areas
NeoplasmsHemic and Lymphatic Diseases
Active Indication
Acute Myeloid Leukemia
Inactive Indication-
Originator Organization
National Center for Advancing Translational SciencesNational Center for Advancing Translational Sciences
Active Organization
National Center for Advancing Translational SciencesNational Center for Advancing Translational Sciences
Inactive Organization-
License Organization-
Drug Highest PhasePreclinical
First Approval Date-
Regulation-

Structure/Sequence

Molecular FormulaC21H26FN5O2
InChIKeySPZWEDSSAIAPRC-HOCLYGCPSA-N
CAS Registry2760328-82-1

Related

100 Clinical Results associated with IRAK1/IRAK4/FLT3 inhibitors(National Center for Advancing Translational Sciences)
Login to view more data
100 Translational Medicine associated with IRAK1/IRAK4/FLT3 inhibitors(National Center for Advancing Translational Sciences)
Login to view more data
100 Patents (Medical) associated with IRAK1/IRAK4/FLT3 inhibitors(National Center for Advancing Translational Sciences)
Login to view more data
1
Literatures (Medical) associated with IRAK1/IRAK4/FLT3 inhibitors(National Center for Advancing Translational Sciences)
14 Nov 2024ACS Medicinal Chemistry Letters
Discovery of IRAK1/4/pan-FLT3 Kinase Inhibitors as Treatments for Acute Myeloid Leukemia
100 Deals associated with IRAK1/IRAK4/FLT3 inhibitors(National Center for Advancing Translational Sciences)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Myeloid LeukemiaPreclinical
United States
National Center for Advancing Translational SciencesNational Center for Advancing Translational Sciences
23 Oct 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free